SUNPHARMA.NSSUNPHARMA.NSNSE
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank64
5Y CAGR+29.7%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
+29.7%/yr
Long-term compound
Percentile
P64
Within normal range
vs 5Y Ago
3.7x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 8.05% |
| Q3 2025 | 36.83% |
| Q2 2025 | 5.99% |
| Q1 2025 | -25.95% |
| Q4 2024 | -4.50% |
| Q3 2024 | 7.21% |
| Q2 2024 | 6.82% |
| Q1 2024 | 5.18% |
| Q4 2023 | 6.24% |
| Q3 2023 | 17.45% |
| Q2 2023 | 1.92% |
| Q1 2023 | -8.38% |
| Q4 2022 | -4.25% |
| Q3 2022 | 9.77% |
| Q2 2022 | 190.50% |
| Q1 2022 | -210.61% |
| Q4 2021 | 0.58% |
| Q3 2021 | 41.74% |
| Q2 2021 | 61.51% |
| Q1 2021 | -51.73% |
| Q4 2020 | 2.19% |
| Q3 2020 | 209.49% |
| Q2 2020 | -514.07% |
| Q1 2020 | -56.23% |
| Q4 2019 | -14.15% |
| Q3 2019 | -23.31% |
| Q2 2019 | 118.20% |
| Q1 2019 | -48.80% |
| Q4 2018 | 667.52% |
| Q3 2018 | -122.27% |
| Q2 2018 | -24.94% |
| Q1 2018 | 258.24% |
| Q4 2017 | -59.94% |
| Q3 2017 | 314.66% |
| Q2 2017 | -134.72% |
| Q1 2017 | -16.86% |
| Q4 2016 | -34.15% |
| Q3 2016 | 9.90% |
| Q2 2016 | 18.67% |
| Q1 2016 | 20.97% |